Publication | Closed Access

Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells

InflammationCytokineAnti-inflammatoryBax-deficient CellsMedicineApoptosisImmunologyCell DeathChronic InflammationPharmacologyCell BiologyCell SignalingApoptotic EffectsOxidative Stress